Detailed Information

Cited 7 time in webofscience Cited 6 time in scopus
Metadata Downloads

An Observational, Multicenter, Cohort Study Evaluating the Antiviral Efficacy and Safety in Korean Patients With Chronic Hepatitis B Receiving Pegylated Interferon-alpha 2a (Pegasys) TRACES Study

Full metadata record
DC Field Value Language
dc.contributor.authorChon, Young Eun-
dc.contributor.authorKim, Dong Joon-
dc.contributor.authorKim, Sang Gyune-
dc.contributor.authorKim, In Hee-
dc.contributor.authorBae, Si Hyun-
dc.contributor.authorHwang, Seong Gyu-
dc.contributor.authorHeo, Jeong-
dc.contributor.authorJang, Jeong Won-
dc.contributor.authorLee, Byung Seok-
dc.contributor.authorKim, Hyung Joon-
dc.contributor.authorJun, Dae Won-
dc.contributor.authorKim, Kang Mo-
dc.contributor.authorChung, Woo Jin-
dc.contributor.authorChoi, Moon Seok-
dc.contributor.authorJang, Jae Young-
dc.contributor.authorYim, Hyung Joon-
dc.contributor.authorTak, Won Young-
dc.contributor.authorYoon, Ki Tae-
dc.contributor.authorPark, Jun Yong-
dc.contributor.authorHan, Kwang-Hyub-
dc.contributor.authorSuk, Ki Tae-
dc.contributor.authorLee, Hyun Woong-
dc.contributor.authorJang, Byoung Kuk-
dc.contributor.authorAhn, Sang Hoon-
dc.date.accessioned2021-08-02T17:26:29Z-
dc.date.available2021-08-02T17:26:29Z-
dc.date.created2021-05-11-
dc.date.issued2016-04-
dc.identifier.issn0025-7974-
dc.identifier.urihttps://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/23844-
dc.description.abstractCurrently, limited data are available regarding the efficacy and safety of pegylated interferon alpha-2a (PEG-IFN α-2a) in Korean patients with chronic hepatitis B (CHB), in whom hepatitis B virus (HBV) genotype C is the most common type. We collected data from 439 patients (HBeAg positive, n=349; HBeAg negative, n=90) with CHB who were treated with PEG-IFN α-2a as a first-line therapy from 18 institutions. Treatment responses at the end of treatment (ET) and at 6 months posttreatment (PT6) were compared between the patients who were treated for 24 weeks versus 48 weeks, and adverse events (AEs) were evaluated. In HBeAg-positive patients, those who received PEG-IFN α-2a for 48 weeks showed significantly higher HBV DNA suppression (HBV DNA<2000IU/mL) than those who were treated for 24 weeks (48 weeks vs 24 weeks; at ET, 44.4% vs 36.7%, P=0.035; at PT6, 35.9% vs 13.3%, P=0.035). The HBeAg seroconversion rate at ET was 18.1% in 48-week treatment group, which is significantly higher than the 2.2% (P<0.001) that was seen in 24-week treatment group. This finding also continued at PT6 (29.0% vs 10.0%, P<0.001). Following 48 weeks of treatment in HBeAg-negative patients, HBV DNA suppression at ET was higher than in HBeAg-positive patients (87.8% vs 44.4%). AEs were typical of those associated with PEG-IFN alpha-2a. In naive Korean HBeAg-positive CHB patients treated with PEG-IFN alpha-2a, higher rates of HBV DNA suppression and HBeAg seroconversion were achieved in the 48-week treatment group than in the 24-week treatment group without additional risk of AEs.-
dc.language영어-
dc.language.isoen-
dc.publisherLIPPINCOTT WILLIAMS & WILKINS-
dc.titleAn Observational, Multicenter, Cohort Study Evaluating the Antiviral Efficacy and Safety in Korean Patients With Chronic Hepatitis B Receiving Pegylated Interferon-alpha 2a (Pegasys) TRACES Study-
dc.typeArticle-
dc.contributor.affiliatedAuthorJun, Dae Won-
dc.identifier.doi10.1097/MD.0000000000003026-
dc.identifier.scopusid2-s2.0-84964612656-
dc.identifier.wosid000375257000004-
dc.identifier.bibliographicCitationMEDICINE, v.95, no.14, pp.1 - 8-
dc.relation.isPartOfMEDICINE-
dc.citation.titleMEDICINE-
dc.citation.volume95-
dc.citation.number14-
dc.citation.startPage1-
dc.citation.endPage8-
dc.type.rimsART-
dc.type.docTypeArticle-
dc.description.journalClass1-
dc.description.isOpenAccessY-
dc.description.journalRegisteredClassscie-
dc.description.journalRegisteredClassscopus-
dc.relation.journalResearchAreaGeneral & Internal Medicine-
dc.relation.journalWebOfScienceCategoryMedicine, General & Internal-
dc.subject.keywordPlusTENOFOVIR DISOPROXIL FUMARATE-
dc.subject.keywordPlusCONTINUOUS ENTECAVIR THERAPY-
dc.subject.keywordPlusON-TREATMENT PREDICTION-
dc.subject.keywordPlusPEGINTERFERON ALPHA-2A-
dc.subject.keywordPlusSUSTAINED RESPONSE-
dc.subject.keywordPlusSTOPPING RULE-
dc.subject.keywordPlusHBV DNA-
dc.subject.keywordPlusHBEAG-
dc.subject.keywordPlusLAMIVUDINE-
dc.subject.keywordPlusCOMBINATION-
dc.identifier.urlhttps://journals.lww.com/md-journal/Fulltext/2016/04050/An_Observational,_Multicenter,_Cohort_Study.4.aspx-
Files in This Item
Appears in
Collections
서울 의과대학 > 서울 내과학교실 > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Jun, Dae Won photo

Jun, Dae Won
COLLEGE OF MEDICINE (DEPARTMENT OF INTERNAL MEDICINE)
Read more

Altmetrics

Total Views & Downloads

BROWSE